These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 32297584)

  • 21. New flavonoid -
    Estrada-Valencia M; Herrera-Arozamena C; Pérez C; Viña D; Morales-García JA; Pérez-Castillo A; Ramos E; Romero A; Laurini E; Pricl S; Rodríguez-Franco MI
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):712-727. PubMed ID: 31852270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease.
    Moussa-Pacha NM; Abdin SM; Omar HA; Alniss H; Al-Tel TH
    Med Res Rev; 2020 Jan; 40(1):339-384. PubMed ID: 31347728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biaryl scaffold-focused virtual screening for anti-aggregatory and neuroprotective effects in Alzheimer's disease.
    Khalid S; Zahid MA; Ali H; Kim YS; Khan S
    BMC Neurosci; 2018 Nov; 19(1):74. PubMed ID: 30424732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Probing Mechanisms and Therapeutic Potential of γ-Secretase in Alzheimer's Disease.
    Wolfe MS
    Molecules; 2021 Jan; 26(2):. PubMed ID: 33450968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Memapsin 2 (beta-secretase) inhibitor drug, between fantasy and reality.
    Ghosh AK; Bilcer G; Hong L; Koelsch G; Tang J
    Curr Alzheimer Res; 2007 Sep; 4(4):418-22. PubMed ID: 17908045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. gamma-secretase as a therapeutic target for treatment of Alzheimer's disease.
    Tomita T; Iwatsubo T
    Curr Pharm Des; 2006; 12(6):661-70. PubMed ID: 16472155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
    Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
    FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Computer-Aided Drug Design of β-Secretase, γ-Secretase and Anti-Tau Inhibitors for the Discovery of Novel Alzheimer's Therapeutics.
    Mouchlis VD; Melagraki G; Zacharia LC; Afantitis A
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31973122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Scope of β-Secretase (BACE1)-Targeted Therapy in Alzheimer's Disease: Emphasizing the Flavonoid Based Natural Scaffold for BACE1 Inhibition.
    Das S; Sengupta S; Chakraborty S
    ACS Chem Neurosci; 2020 Nov; 11(21):3510-3522. PubMed ID: 33073981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.
    Roberds SL; Anderson J; Basi G; Bienkowski MJ; Branstetter DG; Chen KS; Freedman SB; Frigon NL; Games D; Hu K; Johnson-Wood K; Kappenman KE; Kawabe TT; Kola I; Kuehn R; Lee M; Liu W; Motter R; Nichols NF; Power M; Robertson DW; Schenk D; Schoor M; Shopp GM; Shuck ME; Sinha S; Svensson KA; Tatsuno G; Tintrup H; Wijsman J; Wright S; McConlogue L
    Hum Mol Genet; 2001 Jun; 10(12):1317-24. PubMed ID: 11406613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sarsasapogenin: A steroidal saponin from Asparagus racemosus as multi target directed ligand in Alzheimer's disease.
    Kashyap P; Muthusamy K; Niranjan M; Trikha S; Kumar S
    Steroids; 2020 Jan; 153():108529. PubMed ID: 31672628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the β secretase BACE1 for Alzheimer's disease therapy.
    Yan R; Vassar R
    Lancet Neurol; 2014 Mar; 13(3):319-29. PubMed ID: 24556009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The potential of natural product vs neurodegenerative disorders: In silico study of artoflavanocoumarin as BACE-1 inhibitor.
    Razzaghi-Asl N; Karimi A; Ebadi A
    Comput Biol Chem; 2018 Dec; 77():307-317. PubMed ID: 30445338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural Compounds with Anti-BACE1 Activity as Promising Therapeutic Drugs for Treating Alzheimer's Disease.
    Naushad M; Durairajan SSK; Bera AK; Senapati S; Li M
    Planta Med; 2019 Nov; 85(17):1316-1325. PubMed ID: 31618777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BACE1: the beta-secretase enzyme in Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging Alzheimer's disease therapies: inhibition of beta-secretase.
    Citron M
    Neurobiol Aging; 2002; 23(6):1017-22. PubMed ID: 12470797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The structural evolution of β-secretase inhibitors: a focus on the development of small-molecule inhibitors.
    Butini S; Brogi S; Novellino E; Campiani G; Ghosh AK; Brindisi M; Gemma S
    Curr Top Med Chem; 2013; 13(15):1787-807. PubMed ID: 23931442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of new BACE1 inhibitors for treating Alzheimer's disease.
    Kushwaha P; Singh V; Somvanshi P; Bhardwaj T; Barreto GE; Ashraf GM; Mishra BN; Chundawat RS; Haque S
    J Mol Model; 2021 Jan; 27(2):58. PubMed ID: 33517514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against β-secretase and cholinesterases.
    Jung HA; Ali MY; Jung HJ; Jeong HO; Chung HY; Choi JS
    J Ethnopharmacol; 2016 Sep; 191():152-160. PubMed ID: 27321278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.